Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 30, 2017

FibroGen reports positive results from two Phase III trials of roxadustat in anaemia patients

US-based biopharmaceutical firm FibroGen and its division FibroGen China Medical Technology Development has reported positive topline results from the two Phase III clinical trials of roxadustat to treat anaemia in China.

US-based biopharmaceutical firm FibroGen and its division FibroGen China Medical Technology Development has reported positive topline results from the two Phase III clinical trials of roxadustat to treat anaemia in China.

Roxadustat is an orally administered small molecule developed for the treatment of anaemia in dialysis-dependent CKD (DD-CKD) and non-dialysis-dependent CKD (NDD-CKD) patients.

The drug is claimed to be a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which improves endogenous erythropoietin and iron regulation, as well as minimises hepcidin, resulting in increased erythropoiesis.

The double-blind, placebo-controlled NDD-CKD trial conducted in 151 anaemia patients indicated that roxadustat met the primary endpoint by statistically enhancing hemoglobin (Hb) levels, when compared to placebo over eight weeks.

The drug is also reported to have met the secondary end point of Hb response.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
"The results indicated that adverse events were consistent with previous clinical trials of roxadustat in the CKD patients without any new or unexpected safety signals detected."

The second dialysis study in 304 patients randomised to and treated with roxadustat or epoetin alfa, showed Hb change from baseline to the Hb level averaged during the last five weeks of the 26-week treatment period.

The results indicated that adverse events were consistent with previous clinical trials of roxadustat in the CKD patients without any new or unexpected safety signals detected.

FibroGen has partnered with AstraZeneca to develop and commercialise roxadustat in markets such as China and the US, while the firm collaborated with Astellas for Europe, Japan, the Commonwealth of Independent States, the Middle East and Africa.

A roxadustat myelodysplastic syndrome (MDS) Phase II/III clinical trial application (CTA) is currently under review by the China Food and Drug Administration (CFDA), as well as a Phase III trial is being initiated in the US to treat anaemia patients with MDS.


Image: The hand of a person with severe anaemia compared to one without. Photo: courtesy of James Heilman / Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU